Ion channel phosphorylopathy: a link between genomic variation and human disease

Saverio Gentile1

  • 1Department of Molecular Pharmacology and Therapeutics, Loyola University Medical Center, 2160 South First Ave., Bldg. 102, Rm. 3621, Maywood, IL 60153, USA. sagentile@lumc.edu

Chemmedchem
|August 29, 2012
PubMed

Insights

Disease-associated mutations in voltage-gated ion channels (VGIC) may cause malfunction by altering phosphorylation sites. Understanding these "ion channel phosphorylopathies" is key to developing new treatments for related human diseases.

Area of Science:

  • Biophysics
  • Molecular Biology
  • Human Physiology

Background:

  • Voltage-gated ion channels (VGIC) are crucial for physiological processes like muscle contraction and neural signaling.
  • Mutations in VGIC can lead to severe organ dysfunction, impacting patient quality of life and survival.
  • Genomic variations in cytoplasmic domains of ion channels are linked to diseases such as cardiac arrhythmias and neurodegeneration.

Purpose of the Study:

  • To propose a mechanism linking disease-associated mutations in VGIC cytoplasmic domains to channel malfunction.
  • To introduce the concept of "ion channel phosphorylopathies" as a potential molecular basis for these diseases.

Main Methods:

  • This is a concept article, presenting a theoretical framework.
  • It reviews existing knowledge on VGIC structure, function, and disease-associated mutations.
  • It synthesizes information to propose a novel mechanism involving kinase phosphorylation sites.

Main Results:

  • Disease-associated mutations in VGIC cytoplasmic domains may create or disrupt critical phosphorylation sites.
  • These alterations in phosphorylation can directly impact ion channel activity and function.
  • This mechanism provides a potential link between genomic variations and observed channelopathies.

Conclusions:

  • "Ion channel phosphorylopathies" offer a unifying mechanism for understanding how genetic variations cause ion channel dysfunction.
  • Understanding this mechanism is crucial for developing targeted pharmacological strategies for diseases linked to VGIC mutations.
  • Further research into ion channel phosphorylation is warranted to validate this concept and its therapeutic implications.

Related Concept Videos

Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...